Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Bioadaptives (BDPT) Interest Expenses (2019 - 2025)

Historic Interest Expenses for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to $14153.0.

  • Bioadaptives' Interest Expenses rose 4595.24% to $14153.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $43146.0, marking a year-over-year decrease of 6441.01%. This contributed to the annual value of $91978.0 for FY2024, which is 4353.4% down from last year.
  • As of Q3 2025, Bioadaptives' Interest Expenses stood at $14153.0, which was up 4595.24% from $9649.0 recorded in Q2 2025.
  • In the past 5 years, Bioadaptives' Interest Expenses registered a high of $130602.0 during Q4 2021, and its lowest value of $9647.0 during Q1 2025.
  • Moreover, its 5-year median value for Interest Expenses was $38950.0 (2023), whereas its average is $44728.1.
  • Per our database at Business Quant, Bioadaptives' Interest Expenses surged by 37601.21% in 2022 and then tumbled by 8233.64% in 2025.
  • Over the past 5 years, Bioadaptives' Interest Expenses (Quarter) stood at $130602.0 in 2021, then crashed by 31.43% to $89549.0 in 2022, then crashed by 56.5% to $38950.0 in 2023, then tumbled by 75.1% to $9697.0 in 2024, then soared by 45.95% to $14153.0 in 2025.
  • Its last three reported values are $14153.0 in Q3 2025, $9649.0 for Q2 2025, and $9647.0 during Q1 2025.